Moving Beyond Self-Reported Race in Our Understanding of Cardiovascular Medicine.
作者信息
Luo Nancy
机构信息
Sutter Heart and Vascular Institute Sacramento CA.
出版信息
J Am Heart Assoc. 2022 Jun 20;11(12):e026364. doi: 10.1161/JAHA.122.026364.
Abstract
摘要
相似文献
1
Moving Beyond Self-Reported Race in Our Understanding of Cardiovascular Medicine.超越自我报告的种族来理解心血管医学。
J Am Heart Assoc. 2022 Jun 20;11(12):e026364. doi: 10.1161/JAHA.122.026364.
2
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.沙库巴曲缬沙坦：一种新型血管紧张素受体脑啡肽酶抑制剂。
Indian Heart J. 2018 Jul;70 Suppl 1(Suppl 1):S102-S110. doi: 10.1016/j.ihj.2018.01.002. Epub 2018 Jan 8.
3
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.美国黑人中血管紧张素-中性肽链内切酶抑制作用：来自先锋-心力衰竭（PIONEER-HF）试验的数据。
JACC Heart Fail. 2020 Oct;8(10):859-866. doi: 10.1016/j.jchf.2020.06.019. Epub 2020 Sep 9.
4
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).沙库巴曲缬沙坦或依那普利治疗心力衰竭患者中与低血压发作相关的发生率、预测因素和结局：PARADIGM-HF 试验（血管紧张素受体脑啡肽酶抑制剂与血管紧张素转换酶抑制剂前瞻性比较，以确定对心力衰竭全球死亡率和发病率的影响）。
Circ Heart Fail. 2018 Apr;11(4):e004745. doi: 10.1161/CIRCHEARTFAILURE.117.004745.
5
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.沙库巴曲缬沙坦，全球首创的血管紧张素受体脑啡肽酶抑制剂（ARNI）：在高血压、心力衰竭及其他领域的潜在应用。
Curr Cardiol Rep. 2018 Jan 27;20(1):5. doi: 10.1007/s11886-018-0944-4.
6
Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.沙库巴曲缬沙坦双重抑制血管紧张素受体和中性肽链内切酶在慢性收缩性心力衰竭中的应用：解读新的PARADIGM研究
Ann Pharmacother. 2015 Nov;49(11):1237-51. doi: 10.1177/1060028015593093. Epub 2015 Jul 14.
7
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.血管紧张素-脑啡肽酶抑制剂在射血分数保留的心力衰竭中的应用。
N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.
8
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.沙库巴曲缬沙坦抑制中性肽链内切酶治疗心力衰竭：性价比高的降低死亡率方法
J Clin Pharm Ther. 2016 Apr;41(2):119-27. doi: 10.1111/jcpt.12363. Epub 2016 Mar 18.
9
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.血管紧张素受体脑啡肽酶抑制剂治疗射血分数保留心力衰竭：PARAGON-HF 试验的原理和设计。
JACC Heart Fail. 2017 Jul;5(7):471-482. doi: 10.1016/j.jchf.2017.04.013. Epub 2017 Jun 26.
10
Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.沙库巴曲缬沙坦的研究进展与展望：基于射血分数保留的心力衰竭
Biomed Pharmacother. 2022 Nov;155:113701. doi: 10.1016/j.biopha.2022.113701. Epub 2022 Sep 15.
本文引用的文献
1
Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF.射血分数降低的心力衰竭患者中按种族和民族分组的血管紧张素受体脑啡肽酶抑制作用及相关结局：来自CHAMP-HF的数据
J Am Heart Assoc. 2022 Jun 20;11(12):e022889. doi: 10.1161/JAHA.121.022889.
2
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭患者的效果：一项随机临床试验。
JAMA Cardiol. 2022 Jan 1;7(1):17-25. doi: 10.1001/jamacardio.2021.4567.
3
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭患者的生物标志物、健康状况和心脏重构的种族和民族差异。
Circ Heart Fail. 2020 Nov;13(11):e007829. doi: 10.1161/CIRCHEARTFAILURE.120.007829. Epub 2020 Oct 3.
4
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.美国黑人中血管紧张素-中性肽链内切酶抑制作用：来自先锋-心力衰竭（PIONEER-HF）试验的数据。
JACC Heart Fail. 2020 Oct;8(10):859-866. doi: 10.1016/j.jchf.2020.06.019. Epub 2020 Sep 9.
5
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.沙库巴曲缬沙坦与 ACE/ARB 治疗射血分数降低的心力衰竭的疗效比较。
JACC Heart Fail. 2020 Jan;8(1):43-54. doi: 10.1016/j.jchf.2019.08.003. Epub 2019 Dec 11.
6
Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association.非裔美国人的心血管健康：美国心脏协会的科学声明。
Circulation. 2017 Nov 21;136(21):e393-e423. doi: 10.1161/CIR.0000000000000534. Epub 2017 Oct 23.
7
Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
8
The short life of a race drug.
Lancet. 2012 Jan 14;379(9811):114-5. doi: 10.1016/s0140-6736(12)60052-x.
Zotero 插件